Bailard Inc. Increases Holdings in Abbott Laboratories (NYSE:ABT)

Bailard Inc. grew its holdings in Abbott Laboratories (NYSE:ABTGet Rating) by 0.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 80,328 shares of the healthcare product maker’s stock after acquiring an additional 213 shares during the period. Bailard Inc.’s holdings in Abbott Laboratories were worth $11,305,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Morgan Stanley raised its position in Abbott Laboratories by 4.5% during the second quarter. Morgan Stanley now owns 28,562,141 shares of the healthcare product maker’s stock valued at $3,311,209,000 after purchasing an additional 1,233,152 shares during the period. Geode Capital Management LLC grew its stake in Abbott Laboratories by 2.6% in the third quarter. Geode Capital Management LLC now owns 27,129,289 shares of the healthcare product maker’s stock worth $3,195,052,000 after purchasing an additional 691,934 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Abbott Laboratories by 0.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 26,698,119 shares of the healthcare product maker’s stock valued at $3,757,493,000 after acquiring an additional 82,926 shares in the last quarter. Janus Henderson Group PLC boosted its position in Abbott Laboratories by 4.7% during the 3rd quarter. Janus Henderson Group PLC now owns 10,026,692 shares of the healthcare product maker’s stock valued at $1,184,450,000 after acquiring an additional 451,810 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in Abbott Laboratories by 4.6% during the 4th quarter. Fisher Asset Management LLC now owns 8,762,768 shares of the healthcare product maker’s stock valued at $1,233,272,000 after acquiring an additional 386,089 shares in the last quarter. Institutional investors and hedge funds own 73.46% of the company’s stock.

A number of equities analysts recently issued reports on ABT shares. Morgan Stanley reduced their target price on Abbott Laboratories from $157.00 to $151.00 and set an “overweight” rating for the company in a research note on Thursday, January 27th. Bank of America began coverage on Abbott Laboratories in a research report on Tuesday, March 1st. They set a “buy” rating and a $140.00 price target on the stock. UBS Group raised their target price on Abbott Laboratories from $138.00 to $142.00 and gave the company a “buy” rating in a research report on Thursday, January 27th. Raymond James lowered their price objective on Abbott Laboratories from $143.00 to $135.00 and set an “outperform” rating on the stock in a report on Thursday, April 21st. Finally, Credit Suisse Group lifted their price objective on Abbott Laboratories from $138.00 to $139.00 and gave the stock an “outperform” rating in a report on Thursday, January 27th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $138.83.

Shares of ABT stock traded up $1.91 during trading on Friday, hitting $109.88. 6,159,308 shares of the stock traded hands, compared to its average volume of 5,167,185. The firm has a market capitalization of $192.39 billion, a P/E ratio of 25.49, a price-to-earnings-growth ratio of 2.81 and a beta of 0.73. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.40. The firm’s fifty day moving average price is $117.37 and its 200-day moving average price is $124.75. Abbott Laboratories has a 52-week low of $104.63 and a 52-week high of $142.60.

Abbott Laboratories (NYSE:ABTGet Rating) last released its quarterly earnings results on Wednesday, April 20th. The healthcare product maker reported $1.73 EPS for the quarter, beating the consensus estimate of $1.47 by $0.26. The firm had revenue of $11.90 billion for the quarter, compared to analyst estimates of $11 billion. Abbott Laboratories had a net margin of 17.35% and a return on equity of 28.72%. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.32 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 4.82 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, May 16th. Stockholders of record on Friday, April 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 1.71%. The ex-dividend date is Wednesday, April 13th. Abbott Laboratories’s payout ratio is presently 43.62%.

In other Abbott Laboratories news, SVP Randel William Woodgrift sold 964 shares of the business’s stock in a transaction that occurred on Tuesday, March 1st. The stock was sold at an average price of $118.10, for a total value of $113,848.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Julie L. Tyler sold 462 shares of the business’s stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $119.29, for a total value of $55,111.98. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,896 shares of company stock worth $9,299,454. Corporate insiders own 0.52% of the company’s stock.

Abbott Laboratories Profile (Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Read More

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTGet Rating).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.